Free Trial
NASDAQ:BFRG

Bullfrog AI 8/7/2024 Earnings Report

Bullfrog AI logo
$1.27 +0.07 (+5.83%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.26 -0.01 (-0.79%)
As of 08/22/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bullfrog AI EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bullfrog AI Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bullfrog AI Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bullfrog AI Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
BFRG - Bullfrog AI Holdings Inc News | Morningstar
See More Bullfrog AI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bullfrog AI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bullfrog AI and other key companies, straight to your email.

About Bullfrog AI

Bullfrog AI (NASDAQ:BFRG) Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

View Bullfrog AI Profile

More Earnings Resources from MarketBeat